PF-06647263, with the CAS number 1822383-65-2, is a chemical compound that has garnered attention in pharmaceutical research, particularly in the context of treating various diseases. It is classified as a small molecule and is known to act as a selective inhibitor of certain protein kinases, which play crucial roles in cell signaling pathways. The compound's structure typically features functional groups that enhance its binding affinity and specificity towards its target kinases. This selectivity is essential for minimizing off-target effects, which can lead to unwanted side effects in therapeutic applications. PF-06647263 has been investigated for its potential in treating conditions such as cancer and autoimmune diseases, where dysregulation of kinase activity is often implicated. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), are critical for determining its efficacy and safety profile in clinical settings. Ongoing research aims to elucidate its mechanism of action and optimize its therapeutic potential.

PF-06647263

1822383-65-2: PF-06647263, with the CAS number 1822383-65-2, is a chemical compound that has garnered attention in pharmaceutical research, particularly in the context of treating various diseases. It is classified as a small molecule and is known to act as a selective inhibitor of certain protein kinases, which play crucial roles in cell signaling pathways. The compound's structure typically features functional groups that enhance its binding affinity and specificity towards its target kinases. This selectivity is essential for minimizing off-target effects, which can lead to unwanted side effects in therapeutic applications. PF-06647263 has been investigated for its potential in treating conditions such as cancer and autoimmune diseases, where dysregulation of kinase activity is often implicated. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), are critical for determining its efficacy and safety profile in clinical settings. Ongoing research aims to elucidate its mechanism of action and optimize its therapeutic potential.

<p>PF-06647263 (anti-EFNA4-ADC) is a compound targeting EFNA4-ADC SDC, with anti-tumor activity.</p>

CAS 1822383-65-2

PF-06647263

PF-06647263

Ref: TM-T77462